The mecA-27r gene, which encodes PBP2a-27r, was modified by site-specific mutagenesis, resulting in replacement of the N-terminal membrane anchor with a short chelating peptide (CP-PBP2a-27r). retained the same binding affinity for ,-lactam antibiotics as the wild-type enzyme. Approximately 95% pure CP-PBP2a-27r was recovered in a single step by use of chelating-peptide-immobilized metal ion affinity chromatography.
Methicillin-resistant staphylococci cause serious nosocomial infections. These infections represent a leading cause of morbidity and mortality in hospitals and chronic care facilities (2, 6) . Resistance to methicillin in staphylococci has been associated with the production of a membrane-bound, high-molecular-weight penicillin-binding protein (PBP2a) which exhibits weak affinity for penicillins and cephalosporins (1, 8) . Presumably, PBP2a can substitute for the transpeptidase activity of other penicillin-binding proteins and allow survival of the organism in the presence of otherwise lethal concentrations of 3-lactam antibiotics (5) . The mecA gene, which encodes PBP2a, has been cloned, sequenced, and analyzed by in vitro mutagenesis (7, 9, 11, 12) . PBP2a is composed of three domains: an N-terminal membrane-spanning region which anchors PBP2a to the external surface of the cell membrane, a putative transglycosylase domain, and a transpeptidase domain containing the target of ,-lactam antibiotics. Membranebound proteins are generally difficult to purify and crystallize. In a structure-based drug design approach for the development of an inhibitor for PBP2a, the mecA-27r gene from the methicillin-resistant Staphylococcus aureus strain 27r was modified by removing the region that encodes the membranespanning region. Expression of the modified mecA-27r gene in Escherichia coli resulted in production of a fully active watersoluble form of PBP2a-27r (12) . At that point, a facile purification process was desired for recovery of PBP2a that would be suitable for further studies. Kasher and colleagues have described a single-step purification of recombinant human papillomavirus type 16 E7 oncoprotein by use of chelatingpeptide-immobilized metal ion affinity chromatography (CP-IMAC) (3). Here we report the construction of another modified form of PBP2a-27r and the application of CP-IMAC for purification of PBP2a-27r.
In order to apply the CP-IMAC process to the purification of PBP2a-27r, the mecA-27r gene was modified by in vitro mutagenesis (4) . An NcoI restriction site followed by a sequence that encodes a short chelating peptide (MGHWHHH) was inserted by site-specific mutagenesis just upstream of, and in frame with, the triplet which codes for amino acid residue 23 (12) . After mutagenesis, the modified 5' end of the mecA-27r gene was reattached to the remainder of mecA-27r in an E. coli expression vector as described previously (12) . The resulting plasmid, pEWSA31, (Fig. 1C) , contained the modified mecA27r gene encoding an altered version of PBP2a-27r in which the transmembrane domain was removed and replaced with a short chelating peptide (CP-PBP2a-27r). Expression of the modified mecA-27r gene in plasmid pEWSA31 was under the control of the heat-inducible lambda PL promoter.
Modifications made to the protein may have affected its ability to bind penicillin. Therefore, it was necessary to-examine the interaction of CP-PBP2a-27r with 3-lactams. Crude cell extracts from E. coli cells transformed with pEWSA31 were used to assess the penicillin-binding capacity of CP-PBP2a-27r. When tested for binding activity in a competition assay using cefamandole in competition with 1251I-penicillin V, the 50% inhibitory concentration for CP-PBP2a-27r was estimated to be between 90 and 180 ,ug of cefamandole per ml (Fig. 2) . The wild-type form of this enzyme from staphylococcal membranes also exhibited a 50% inhibitory concentration of between 90 and 180 p,g of cefamandole per ml under similar conditions CP-PBP2a-27r was produced by introducing plasmid pEWSA31 into E. coli DH5a and exposing these cells to conditions that induced expression of the modified mecA-27r gene. A sample from an overnight broth culture of E. coli DH5a containing plasmid pEWSA31 was streaked onto TY (Bacto-Tryptone, 10 g/liter; Bacto-yeast extract, 5 g/liter; Bacto-Agar, 15 g/liter) agar plates containing 10 ,ug of tetracycline per ml. The inoculated plates were incubated for 4 h at 30°C. Expression of CP-PBP2a-27r was induced by increasing the temperature of incubation to 41°C for an additional 4 h. Under these conditions, the bulk of CP-PBP2a-27r was found in inclusion bodies (granules). Alternatively, a broth culture could be used for expression. To isolate granules containing CP-PBP2a-27r, 1 Binding efficiency of cefamandole to CP-PBP2a-27r. Competition experiments were performed as described previously (12) . A sample containing CP-PBP2a-27r was exposed to various concentrations of cefamandole and incubated at 37°C for 10 min. An equal volume of "2I-penicillin V (96 ,ug/ml) was added to the reaction mixtures and incubated for an additional 10 min at 37°C. The reactions were stopped by addition of gel running dye containing an excess of unlabeled penicillin V, and mixtures were loaded onto an 8% polyacrylamide gel. After separation of the proteins by electrophoresis, the gel was dried and exposed to X-ray film. The arrow indicates the estimation of a 50% inhibitory concentration (150), which is the concentration of cefamandole at which 50% of the binding of '`Ipenicillin V to CP-PBP2a-27r was inhibited. distilled water. Granules harvested by centrifugation (12,000 x g for 20 min) from the final wash were resuspended in water and stored at -20°C.
In order to proceed with protein purification, it was necessary to release the proteins trapped in the granules. Granules containing CP-PBP2a-27r were solubilized in sulfitolysis reagent (7.5 M urea, 0.5 M Tris-HCl, 100 mM Na2SO3, 10 mM Na2S406, pH 8.2) and filtered through a 0.45-,m-pore-size filter before application to the Zn(II) IMAC purification column. Lane 1 of the inset in Fig. 3 illustrates the proteins released from the granules.
The CP-IMAC purification procedure used to purify CPPBP2a-27r was modified from the method described by Kasher and coworkers (3) . Briefly, an HR 10/10 Pharmacia column was poured with Pharmacia Fast-Flow Chelating Gel, connected to a fast protein liquid chromatography LCC500 fraction collection system (Pharmacia Biotech, Piscataway, N.J.), and washed with 5 ml of distilled water. The metal ion [Zn(II)] was loaded onto the column by applying 6 ml of a 50 mM ZnC12 solution to the column. The metal-loaded column was washed with 5 ml of distilled water and equilibrated with buffer A (50 mM NaH2PO4, 0.5 M NaCl, 7 M urea, pH 8.0). A 2-ml sample of the sulfitolysis solution containing the solubilized proteins from granules was loaded onto the column. The column was washed with buffer A at 0.25 m/min until the A280 of the eluate was negligible, generally about 30 min. The bound material was then eluted by introducing a displacing ligand.
Buffer B, used to generate the imidazole gradient, consisted of 0.5 M imidazole, 50 mM NaH2PO4, 0.5 M NaCl, and 7 M urea (pH 8.0). A gradient of 0 to 60% buffer B was applied to the column over 90 min to elute CP-PBP2a-27r. The majority of the protein was eluted in the first peak, as illustrated by the A280 tracing in Fig. 3 
